PTPRD Antibody - BSA Free

Western Blot: PTPRD Antibody - BSA Free [NBP2-94767] -

Protein tyrosine phosphatase receptor type D knockdown attenuates neuropathic pain following CCI. (A) Representative images of GFP (green) and NeuN staining (red) 14 days after shPTPRD injection in the DRG. Scale bar, 100 μm. (B) qRT-PCR analysis of the relative expression of PTPRD in DRGs transfected with shCtrl or shPTPRD after CCI. N = 3, ***p < 0.001. (C) Western blot of PTPRD in DRG tissues transfected with shCtrl or shPTPRD after CCI. Each experiment was repeated three times. (D) Quantitative analysis of data in (C). GAPDH served as the loading control. N = 3, ***p < 0.001. (E) Schedule of lentivirus administration, surgery, and behavioral testing. (F–H) Paw withdrawal threshold, paw withdrawal latency, and paw withdrawal frequency prior to virus injection (BL), on the day of surgery, or 1, 3, 5, 7, 14, and 21 days after CCI. N = 6 mice per group. CCI + shPTPRD vs. CCI + shCtrl, *p < 0.05, **p < 0.01, ***p < 0.001. CCI vs. sham, #p < 0.05, ##p < 0.01, ###p < 0.001. Statistical comparisons were performed using unpaired Student’s t-test (B,D) or two-way ANOVA with Tukey’s post hoc test (F–H). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35493326), licensed under a CC-BY license. Not internally tested by Novus Biologicals.